Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fimasartan

    • 238 Accesses

    • 9 Citations

    This is a preview of subscription content, log in to check access.

    Table I
    Table II

    References

    1. 1.

      A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60 mg (Phase 3). ClinicalTrials.gov Identifier: NCT01258673.

    2. 2.

      Chi YH, Lee H, Paik SH, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of fimasartan, a novel angiotensin II receptor antagonist, following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs 2011. In press.

    3. 3.

      Kim JW, Kim BR, Shim JH, et al. Pharmacokinetic interaction between a novel angiotensin II receptor blocker, fimasartan, and hydrochlorothiazide in healthy volunteers. 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics: abstr. PII-44, 17 Mar 2010. Available from URL: http://www.ascpt.org/annualmeeting2010/index.cfm.

    4. 4.

      Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. Epub 2011 Mar 9.

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Fimasartan. Am J Cardiovasc Drugs 11, 249–252 (2011). https://doi.org/10.2165/11533640-000000000-00000

    Download citation

    Keywords

    • Atorvastatin
    • Essential Hypertension
    • Amlodipine
    • Hydrochlorothiazide
    • Valsartan